Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.

Abstract: Provided are a labelling agent including a compound of the following Formula 1, a labelling composition, a method of labelling a protein with the labelling agent, and a method of detecting the protein using the labelling agent: wherein R1, R2, R3, R4, R5, R6, and R8 are independently H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl, R7 is H or —NR9R10, R9 and R10 are independently H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl, X is —NR11, —O, or S, R11 is H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl, Y is —OR12 or —NR13R14, R12 is H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl, and R13 and R14 are independently H, substituted or unsubstituted —C1-10-alkyl-, —C2-10-alkenyl, or —C2-10-alkynyl.

Abstract: The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

Abstract: The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAb1 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including Denge virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fcy receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.

Abstract: The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.

Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.

Abstract: Epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in treatment of cancer are thus provided herewith.

Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.

Abstract: The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.

Abstract: The present application is directed to heterodimeric antibodies and methods of use.

Abstract: A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.

Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.

Abstract: Novel anti-interleukin 3 (IL-3) antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the N-terminal 20 amino acids of the amino acid sequence of human IL-3 according to SEQ ID No. 1, and preferably to a sequence motif SWVN (SEQ ID NO: 2). The antibodies can be used in diagnostic methods for the determination of IL-3 levels in body fluids, preferably in corresponding ELISA assays, but also in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated levels of IL-3 in a patient, especially rheumatoid arthritis.

Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.

Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.

Abstract: The present invention relates in general to the field of TNF ligand family members. In more detail the present invention relates to polypeptides comprising at least three components A, each of which comprises the sequence of a TNF homology domain (THD) of a TNF ligand family member, or a functional derivative thereof, and comprising at least one component B consisting of a VL region and a VH region linked directly to each other with a linker sequence L which has a length of <12 amino acids. Furthermore, the present invention also relates to nucleic acids encoding such polypeptides and pharmaceutical compositions thereof.

Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.

Abstract: The present invention is directed to sequence-optimized CD 123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

Abstract: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab?, F(ab?)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.

Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.

Abstract: Certain embodiments are directed to composition and methods related to DCLK1-S specific binding agents.

Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.

Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.

Abstract: Described are a method for processing cellulose-containing biomass and the use of methanesulfonic acid for processing cellulose-containing biomass, especially for the pretreatment of cellulose-containing biomass prior to saccharification.

Abstract: The present invention relates to a phase-stable suspension of cellulose II in water, having a high water retention capacity and a cellulose concentration between 0.1 and 5.0% by weight, a method of its preparation, and its use.

Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

Abstract: A nano-composition that includes nanoparticles, a method of forming the nano-composition, and a method of using the composition. The nanoparticles include a polycationic polymer ionically bonded to one or more polyanionic Glycosaminoglycans (GAGs), wherein the polycationic polymer is chitosan, methylated chitosan, poly L-Lysine, or poly L-Arginine.

Abstract: A technique of improving the hydrogenation reaction of diene-based polymers, present in aqueous suspension, by in-situ synthesizing the catalyst in the presence of a specific aliphatic alcohol is disclosed. The process allows the selective hydrogenation of the carbon-carbon double bonds in the diene-based polymers with a high degree of hydrogenation and short reactions times. The improved process eliminates the complicated catalyst synthesis operations so far necessary.

Abstract: Disclosed are an end-modified conjugated diene-based polymer configured such that the end of a conjugated diene-based polymer is coupled with an aminosilane-based end modifier, and a method of preparing the same.

Abstract: A system and method for startup of a polyolefin reactor temperature control system having a first reactor temperature control path, a second reactor temperature control path, and a shared temperature control path. In some embodiments, during startup the second reactor temperature control path is configured to allow the temperature of a second reactor to rise due to the heat of the exothermic polymerization reaction occurring within reactor until reaching a predetermined setpoint temperature. In other embodiments, during startup a first reactor temperature control path is configured to include a heat exchanger used as a cooler, and a second reactor temperature control path is configured to include a heat exchanger used as a heater, to raise the temperature of the second reactor until reaching a predetermined setpoint temperature.

Abstract: The present invention is directed to an entity comprising a particle attached to at least one polymer M through one or several supramolecular interactions -A-B- constituted by 2 to 8 hydrogen bonds X-H-Y, wherein A and B are functional groups respectively grafted to P and M thus forming the particle-containing entity P-(A-B-M)x with x being greater than or equal to 1, functional group(s) B being positioned at one end of the polymeric chain of polymer M, X and Y are heteroatoms present in A and B functional groups, H is hydrogen, and M has a degree of polymerization comprised between 5 and 1000, preferably ranging from 5 to 500. The invention is also directed to a method for preparing this particle-containing entity P-(A-B-M)x, a method for sequentially forming and breaking the supramolecular interactions -A-B- in said particle-containing entity P-(A-B-M)x and dispersions comprising the same.

Abstract: The invention describes a process for producing a diene polymer, the process comprising the following steps in this order: i) polymerizing one or more diene monomers in the presence of a catalyst composition to give a reaction mixture; ii) adding to the reaction mixture one or more alkoxysilane compounds; iii) adding S2Cl2, SCl2, SOCl2, S2Br2, SOBr2 or a mixture thereof to the reaction mixture; and iv) optionally adding a protic agent to the reaction mixture so as to deactivate the catalyst. The invention further includes polymers that are obtainable according to this process, as well as products including the polymer.

Abstract: The present disclosure discloses a catalyst composition for olefin polymerization, comprising the following components: a): a solid catalyst component containing magnesium, titanium, halogens, and at least one internal electron donor having a lone pair of electrons; b): an aluminum alkyl compound; and c): an external electron donor containing a first external electron donor C1, which is a malonate compound. In the present disclosure, a catalyst composition having an external electron donor that contains a malonate compound is used in olefin polymerization, in particular propene polymerization, and can significantly improve catalytic activity and hydrogen response of the catalyst and expand molecular weight distribution of polymers, which facilitates development of different polymers.

Abstract: A process for producing water-absorbing polymer particles, comprising the steps of thermal cracking of bionaphtha in the presence of steam, removing propene and at least some of the propane, gas phase oxidation to give acrylic acid and polymerization to give water-absorbing polymer particles.

Abstract: A process for the preparation of branched polybutadiene having a high content of 1,4-cis units which comprises polymerizing butadiene in the presence of at least one organic solvent, and in the presence of: a) a catalytic system prepared in situ including: (a1) at least one neodymium carboxylate, (a2) at least one alkyl compound of aluminum, (A3) at least one alkyl compound of aluminum containing at least one halogen atom, and b) at least one organic ester containing at least one halogen atom. Said branched polybutadiene having a high content of 1,4-cis units, depending on the branching degree and molecular weight distribution, can be advantageously used in various applications ranging from the modification of plastic materials [production, for example, of high impact polystyrene (HIPS)] to the production of tires, in particular the production of treads and/or of sidewalls of tires.

Abstract: The present invention pertains to a metallocene catalyst based on a transition metal of groups 4 or 5 of the periodic table prepared by the immobilization of a metallocene complex on a support modified with hybrid soluble silica, prepared by a non-hydrolytic sol-gel process. There is also described a process for preparing said catalyst. The supported metallocene catalyst of the present invention has the advantages of high catalytic activity, morphology, besides the fact of producing copolymers of ethylene with alpha-olefins having molecular behavior that will bring benefits in mechanical properties, such as resistance to tearing, piercing and impact, as well as improved optical and weldability properties.

Abstract: The present invention relates to a novel ligand compound, a transition metal compound, and a catalytic composition including the same. The novel ligand compound and the transition metal compound of the present invention are useful as a polymerization reaction catalyst in preparing an olefin-based polymer having low density. In addition, an olefin polymer polymerized using a catalytic composition including the transition metal compound is capable of being prepared to a high molecular weight product having a low melt index (MI).

Abstract: The invention relates to reflective particles containing a resin containing a structural unit derived from a compound represented by the following Formula (1), wherein in the formula (1), R represents a polymerizable group except a vinyl group, Ar represents an aromatic group, and W represents a single bond or a divalent linking group.

Abstract: Polymer/copper combination that can selectively target and kill cancer cells are described. Materials can include the reaction product of a biocompatible hydrophilic polymer and pyridine-2-thiol containing monomer. The copolymer reaction product can include pyridine-2-thiol side groups pendant to the backbone via a disulfide linkage. The hydrophilic component can form the polymer backbone and/or can form hydrophilic pendant groups off of the backbone. Copper ions can be associated with the copolymer.

Abstract: A process for producing water-absorbing polymer particles having high free swell rate and high centrifuge retention capacity with simultaneously high permeability of the swollen gel bed by polymerization of an aqueous monomer solution in a polymerization reactor having at least two shafts (kneaders) which rotate in an axially parallel manner, subsequent extrusion at high temperatures and thermal surface postcrosslinking.

Abstract: The present invention includes vinyl ether functional oligomers and methods for their preparation, the method including alternating free radical copolymerization of a dialkyl maleate or dialkyl fumerate monomer with a multifunctional vinyl ether monomer in the presence of a solvent with a high chain transfer constant. Also within the scope of the invention are uses for the vinyl ether functional oligomers compositions of this invention, including radiation curable coatings, adhesives, printing inks and composites.

Abstract: The invention provides novel flame-retardant polymers and materials, their synthesis and use. More particularly, the flame-retardant polymers are deoxybenzoin-derived polymers.

Abstract: There is provided a copolymer having the general structure below, wherein a, b, and d are molar ratios varying between about 0.01 and about 0.90 and c is a molar ratio varying between about 0.01 and about 0.90; A1 represents monomer units comprising a cyano-containing pendant group in which the cyano is not directly attached to the backbone of the copolymer; A2 represents monomer units comprising two or more hydrogen bonding sites; A3 represents monomer units that increase solubility in organic solvents; and A4 represents monomer units that increase solubility in aqueous alkaline solutions. There is also provided a near-infrared radiation-sensitive coating composition comprising this copolymer as well as a positive-working thermal lithographic printing plate comprising a near-infrared radiation-sensitive coating comprising this copolymer, a method of producing such a printing plate, and finally a method of printing using such a printing plate. Formula (I).

Abstract: There is provided a composition for forming a hard coat layer which has high slippage and is excellent in water/oil repellency and also has antifouling properties such as fingerprint resistance and dirt wiping-off properties, and which is curable through ultraviolet irradiation in a nitrogen atmosphere or an air atmosphere that is generally used. A silicon-containing highly branched polymer obtained by polymerization of a monomer A having two or more radically polymerizable double bonds in a molecule and a monomer B having a polysiloxane chain and at least one radically polymerizable double bond in a molecule in the presence of a polymerization initiator D in an amount of 5 to 200% by mole relative to the number of moles of the monomer A; a curable composition including the highly branched polymer; a cured film obtained from the composition; and a hard coat film obtained by use of the composition.

Abstract: A process of forming a flame retardant material from furan dicarboxylic methyl ester (FDME) includes converting an FDME molecule to a 2,5-furan dicarbonyl dichloride (FDCC) molecule and chemically reacting the FDCC molecule with a phosphorus-containing material to form an FDME-based flame retardant material that includes a phosphorus-based flame retardant moiety.

Abstract: The present invention is a method for decomposing a polymer material by chemically decomposing a polymer material containing a first monomer and a second monomer in a mixture of the polymer material with the first monomer or a derivative of the first monomer to produce a chemical raw material. A relationship between a proportion of number of molecules of the second monomer to number of molecules of the first monomer in a reaction system for decomposing the polymer material and the molecular weight of the chemical raw material produced in the reaction system is acquired in advance (S101). Subsequently, an addition mount of the derivative of the first monomer to be added to the polymer material is determined based on the above relationship (S102). The first monomer in the addition amount determined is then mixed with the polymer material (S103).

Abstract: The present invention relates to a method to form a polyurethane material, a catalyst composition comprising metalized polyhedral oligomeric silsesquioxanes (POMS) compounds in combination with reactive compounds suitable to be used to provide a polyurethane material and the polyurethane material obtained using the catalyst composition.

Abstract: The present invention provides polyurethanes including a reaction product of components including: (a) an isocyanate functional urethane prepolymer comprising a reaction product of components including: (i) about 1 equivalent of at least one polyisocyanate; and (ii) about 0.1 to about 0.5 equivalents of at least one diol having 2 to 18 carbon atoms; and (b) about 0.05 to about 0.9 equivalents of at least one branched polyol having 4 to 18 carbon atoms and at least 3 hydroxyl groups; and (c) up to about 0.9 equivalents of at least one polyol different from branched polyol (b) and having 2 to 18 carbon atoms, wherein the reaction product components are essentially free of polyester polyol and polyether polyol; compositions, coatings and articles made therefrom and methods of making the same.

Abstract: A polyisocyanate composition is produced by reaction of bis(isocyanatomethyl) cyclohexane with trimethylolpropane, and contains a trimethylolpropane-monomolecular-body obtained by reaction of three molecules of bis(isocyanatomethyl) cyclohexane with one molecule of trimethylolpropane, and a trimethylolpropane-bimolecular-body obtained by reaction of five molecules of bis(isocyanatomethyl) cyclohexane with two molecules of trimethylolpropane; and the molar ratio of trimethylolpropane-monomolecular-body relative to trimethylolpropane-bimolecular-body (trimethylolpropane-monomolecular-body/trimethylolpropane-bimolecular-body) contained in the polyisocyanate composition is 1.5 or more and 4.5 or less.

Abstract: A method of forming a flame resistant flexible polyurethane foam that has a V-0 rating, according to Underwriters Laboratories Standard 94 Flammability Test, includes forming a reaction mixture that has an isocyanate component and an isocyanate-reactive component, and the isocyanate-reactive component includes a polyol component. The isocyanate component includes at least 30 wt % of a biuret modified aromatic diisocyanate, based on a total weight of the isocyanate component, and an isocyanate index of the reaction mixture is less than 100. The polyol component includes at least 5 wt % of a filled polyether polyol and at least 65 wt % of one or more other polyols that are different from the filled polyether polyol, based on a total weight of the isocyanate-reactive component.